menu
    • menu
    [{"orgOrder":0,"company":"Enanta Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Zelicapavir","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Enanta Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Enanta Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Enanta Pharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Zelicapavir

    Menu

    Zelicapavir

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Enanta Pharmaceuticals

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed

                            Enanta Pharmaceuticals

                            U.S.A arrow
                            RNA Therapeutics
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zelicapavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Enanta Reports Positive Phase 2 Results for Zelicapavir in Respiratory Syncytial Virus

                            Details : EDP-938 (zelicapavir) is a RSV N-protein inhibitor, small molecule drug candidate. It is being evaluated for the treatment of respiratory syncytial virus infection.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 09, 2024

                            Lead Product(s) : Zelicapavir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth